company background image
DIABIO logo

Diagonal Bio OM:DIABIO Stock Report

Last Price

SEK 0.013

Market Cap

SEK 15.3m

7D

-10.6%

1Y

-87.5%

Updated

13 Mar, 2025

Data

Company Financials

Diagonal Bio AB (publ)

OM:DIABIO Stock Report

Market Cap: SEK 15.3m

DIABIO Stock Overview

Operates as a biotechnology company in Sweden. More details

DIABIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Diagonal Bio AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Diagonal Bio
Historical stock prices
Current Share PriceSEK 0.013
52 Week HighSEK 0.16
52 Week LowSEK 0.0063
Beta-1.82
1 Month Change-31.52%
3 Month Change-50.78%
1 Year Change-87.52%
3 Year Change-99.75%
5 Year Changen/a
Change since IPO-99.92%

Recent News & Updates

Recent updates

Shareholder Returns

DIABIOSE BiotechsSE Market
7D-10.6%-3.2%-3.1%
1Y-87.5%-1.8%3.1%

Return vs Industry: DIABIO underperformed the Swedish Biotechs industry which returned -4.1% over the past year.

Return vs Market: DIABIO underperformed the Swedish Market which returned 3.4% over the past year.

Price Volatility

Is DIABIO's price volatile compared to industry and market?
DIABIO volatility
DIABIO Average Weekly Movement22.5%
Biotechs Industry Average Movement9.2%
Market Average Movement6.0%
10% most volatile stocks in SE Market13.1%
10% least volatile stocks in SE Market3.4%

Stable Share Price: DIABIO's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: DIABIO's weekly volatility has decreased from 32% to 23% over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
20204Karin Wehlindiagonalbio.com

Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.

Diagonal Bio AB (publ) Fundamentals Summary

How do Diagonal Bio's earnings and revenue compare to its market cap?
DIABIO fundamental statistics
Market capSEK 15.31m
Earnings (TTM)-SEK 10.20m
Revenue (TTM)SEK 1.21m

12.7x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DIABIO income statement (TTM)
RevenueSEK 1.21m
Cost of Revenue-SEK 58.00k
Gross ProfitSEK 1.27m
Other ExpensesSEK 11.47m
Earnings-SEK 10.20m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

May 14, 2025

Earnings per share (EPS)-0.0084
Gross Margin104.79%
Net Profit Margin-842.98%
Debt/Equity Ratio0%

How did DIABIO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/13 04:20
End of Day Share Price 2025/03/13 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Diagonal Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.